Bibliographical note

Funding Information:
Funding/Support: This study received no funding. Financial Disclosures: Reiko Arita holds patents on the infrared meibography technique (Japanese patent registration no. 5281846; US patent publication no. 2011-0273550A1; European patent publication no. 2189108A1), is a consultant for Topcon Company (Tokyo, Japan) and Technopia Japan (Tokyo, Japan); in addition, she has received lecture fees from Santen, Senju, Lumenis, Inami, J&J, Alcon, and Novartis. Gus Gazzard has received grants from Thea and Santen, consulting fees from Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, Thea, and Zeiss, and lecture fees from Alcon, Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, and Thea. Steffen Heegaard has received lecture fees from Alcon, Sanofi, Eye-GO, and Santen. Cintia S. de Paiva has received research grants from Yuyu Pharma, Allysta Pharma, and Roche. Goran Petrovski has received lecture fees from Allergan, Alcon, and Santen. Tor P. Utheim is cofounder and co-owner of The Norwegian Dry Eye Clinic and the Clinic of Eye Health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausch&Lomb, Bayer, European School for Advanced Studies in Ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals, and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. In addition, he is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, and a Consultant at the Norwegian Association for the Blind and Partially Sighted. Miriam Kolko has received lecture fees from Santen, Allergan/Abbvie, Thea Pharmaceutical, is an advisory board member in Allergan/Abbvie and Thea Pharmaceutical, an expert group member in Santen, has a collaboration grant from Thea Pharmaceutical, and is a consultant for Abbvie and Thea Pharmaceutical. The other authors indicate no financial support or conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship. Declaration of Competing Interest: The authors have no conflicts of interest to disclose related to the present study. Acknowledgments: The authors wish to acknowledge the contributions of survey participants in the ASGARD study group: Augusto Azuara-Blanco, Alex Day, Alexander Schuster, Anders Højslet Vestergaard, Andy McNaught, Anssam Jamal Assad Al-Shamary, Anthony King, Reiko Arita, Biljana Spaseva-Karanfilova, Barbara Cvenkel, Bek Tashbayev, Benjamin Frankfort, Christophe Baudouin, Cintia de Paiva, Jong-Suk Song, Ted Garway-Heath, Daniella Bach-Holm, Karl Mercieca, Erlend Sommer Landsend, Elisabeth Messmer, Eduardo Rocha, Carl Erb, Florian Rüfer, Frances Meier-Gibbons, Shima Fukuoka, Galina Dimitrova, Gianni Virgili, Goran Petrovski, Gus Gazzard, Gysbert-Botho van Setten, Hari Jayaram, Gabor Hollo, Ingrida Januleviciene, Ilgaz Yalvac, Jae Lim Chung, Jan Henrik Simonsen, Jeremias Galletti, Jim Kirwan, Jia Yin, Jayter de Paula, Jukka Moilanen, Kai Kaarniranta, Lars Loumann Knudsen, Ljubo Znaor, Manfred Zierhut, Matilda Chan, Miriam Kolko, Michael Læssø, Mohammed Kashaf Farooq, Monica Alves, Niko Setälä, Pavi Agrawal, Per Riise, Petra Schollmayer, Peter Fahmy, Philipp Steven, Simon Von Spreckelsen, Reza A. Badian, Saj Ahmed, Simona Nicoara, Søren Berndt Hansen, Stephen C Pflugfelder, Steffen Heegaard, Niklas Telinius, Troels Brynskov, Tor Utheim, Valeria Mocanu, Verena Prokosch-Willing, Vito Romano, Vladimir Poposki, Yolanda Diebold.

Funding Information:
Funding/Support: This study received no funding. Financial Disclosures: Reiko Arita holds patents on the infrared meibography technique (Japanese patent registration no. 5281846; US patent publication no. 2011-0273550A1; European patent publication no. 2189108A1), is a consultant for Topcon Company (Tokyo, Japan) and Technopia Japan (Tokyo, Japan); in addition, she has received lecture fees from Santen, Senju, Lumenis, Inami, J&J, Alcon, and Novartis. Gus Gazzard has received grants from Thea and Santen, consulting fees from Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, Thea, and Zeiss, and lecture fees from Alcon, Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, and Thea. Steffen Heegaard has received lecture fees from Alcon, Sanofi, Eye-GO, and Santen. Cintia S. de Paiva has received research grants from Yuyu Pharma, Allysta Pharma, and Roche. Goran Petrovski has received lecture fees from Allergan, Alcon, and Santen. Tor P. Utheim is cofounder and co-owner of The Norwegian Dry Eye Clinic and the Clinic of Eye Health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausch&Lomb, Bayer, European School for Advanced Studies in Ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals, and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. In addition, he is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, and a Consultant at the Norwegian Association for the Blind and Partially Sighted. Miriam Kolko has received lecture fees from Santen, Allergan/Abbvie, Thea Pharmaceutical, is an advisory board member in Allergan/Abbvie and Thea Pharmaceutical, an expert group member in Santen, has a collaboration grant from Thea Pharmaceutical, and is a consultant for Abbvie and Thea Pharmaceutical. The other authors indicate no financial support or conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship.